M22-A3 strongly recommends using at least 40 patient samples (range covering the reportable interval) against a reference method (e.g., LC-MS/MS vs. immunoassay). For interferences, the guideline specifies testing:
Fundamental methodology
: Responsible for proper storage and transport to prevent damage (e.g., freezing or overheating). Users (Laboratories) clsi m22a3 pdf
Different commercial systems have different strengths regarding NFB. M22-A3 compares these systems. M22-A3 strongly recommends using at least 40 patient
Yes. The standard requires lot-level testing per manufacturer. Different manufacturers may use different formulations or production processes, so performance can vary. LC-MS/MS vs. immunoassay). For interferences
: Guidelines for preparing inoculum (such as matching a 0.5 McFarland standard) and isolation streaking methods for quality verification. Key Specifications